With Samsung Biologics, the Korean conglomerate presents itself as a diligent subcontractor for labs that are increasingly focusing on research.
The concrete and glass cubes pile up on the polders reclaimed from the muddy waters of the Yellow Sea. On the horizon, the rugged mountains of North Korea stand out above Incheon Bay in Songdo, the new biotech frontier of the Samsung empire. Here, sixty kilometers west of Seoul, Samsung Biologics will inaugurate a fourth production line of biological drugs (derived from a living cell, not chemistry), to increase it to a capacity of 620,000 liters in October. 2023, asserting itself as the largest global subcontractor in the sector.
It already manufactures vaccines against Covid for Moderna, but also several treatments for large pharmacy labs, with the ambition of capturing 30% of the rapidly developing biological drug market. “We will continue to seal new partnerships with major global pharmaceutical groups such as AstraZeneca and Roche. Due to Covid, the drug outsourcing market…
This article is for subscribers only. You have 70% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login